For 10 consecutive patients in our unit who did not show a significant rise in blood progenitor cells within 14 days following chemotherapy and G-CSF, we increased the G-CSF dose from 5 to 10 g/kg/day (n = 9) or from 10 to 15 g/kg/day (n = 1). As a result, there were significant increases in total yield as well as yield per apheresis of mononuclear cells, CD34
With the discovery that the number of circulating hematopoietic progenitor cells dramatically increases during the recovery phase of myelo-suppressive chemotherapy, 1 various chemotherapy regimens were employed to mobilize peripheral blood stem cells (PBSC) for transplant. [2] [3] [4] However, the cytopenic phase following myelo-suppressive chemotherapy is often associated with significant morbidity or even mortality. 3, 5 With the advent of hematopoietic growth factors (HGF), the use of combined chemotherapy and HGF in mobilizing PBSC results in a shorter cytopenic phase, reduction of infection risks and duration of hospital stay and enhances PBSC yield compared to mobilization with chemotherapy alone. 4, [6] [7] [8] [9] [10] Nevertheless, the dosages and scheduling of chemotherapy and HGF to optimize the cell yield, and hence the successful outcome of mobilization, remain to be studied.
A continuing challenge of PBSC mobilization protocols is that there remains a proportion of patients from whom insufficient progenitor cells can be harvested. In most series employing a combination of chemotherapy and G-CSF, there are 20-30% of patients who show no significant mobilization. In allogeneic donors receiving G-CSF alone for progenitor cell mobilization, escalating the dose of G-CSF to more than 10 g/kg/day appears to provide a higher yield. 11 However, in the autologous setting, whether dose escalation above 5 g/kg/day or 300 g/day in chemotherapy plus G-CSF mobilization will salvage failed mobilization is still an important question to be answered.
In this report, we describe 10 consecutive patients in whom chemotherapy plus conventional dose G-CSF failed to achieve sufficient progenitor cell yield. Following an increase of the dose of G-CSF, sufficient progenitor cells were harvested in six. Our results strongly suggest a dosedependent response of PBSC mobilization by G-CSF when used with chemotherapy.
Materials and methods

Patients and mobilization regimens
Out of 53 patients who were mobilized for PBSC collection between October 1995 and August 1996 at Royal Adelaide Hospital, Adelaide, there were 10 (19%) patients whose cell yields were below the threshold values for PBSCT. Nine of the patients were adults with hematological malignancies and the tenth patient was a 3-year-old boy with optic glioma referred from Women's and Children's Hospital, Adelaide. Eight of the adults were mobilized with cyclophosphamide 5 g/m 2 i.v. over 8 h on day 1 followed by G-CSF 5 g/kg/day s.c. starting on day 4 until collection was completed. 
Apheresis and cryopreservation
PBSC collection was performed with a Fenwal CS 3000 continuous flow cell separator (Baxter, IL, USA). Apheresis was initiated when the leukocyte count was above 1 × 10 9 /l and preferably when the peripheral blood CD34
+ cell count reached 20 × 10 6 /l. Collection was continued daily until a sufficient total cell yield was harvested or if the daily yield failed to increase despite insufficient total cell yield or to a maximum of five aphereses. Mononuclear cells (MNC) of the harvest were separated on a Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient and suspended in 10% dimethyl sulfoxide and 20% autologous plasma. Cryopreservation was achieved with a controlled rate freezer at −1°C/min down to −80°C and then transferred into liquid nitrogen for storage.
CD34
+ cell enumeration
The number of CD34 + cells in the peripheral blood and in the apheresis product was assessed on each day of harvest. A volume of 100 l with approximately 5 × 10 5 MNC was incubated with 10 l of CD34 antibody (HPCA-2-PE; Becton Dickinson, Mountain View, CA, USA) at room temperature in the dark for 20 min. The cells were then washed twice with 2 ml of Hank's balanced salt solution with 2% fetal calf serum, and then suspended in 250 l of FACS fixative solution (1% vol/vol formaldehyde in Dulbecco's phosphate-buffered saline). A mouse antibody IgG1-PE (Dakopatts) was used in control samples. Analysis was performed within 24 h using a Coulter Profile II flow cytometer (Coulter Electronics, Miami, FL, USA) counting 10 5 events per sample.
CFU-GM assay
MNC were seeded at a density of 0.5 to 3 × 10 5 /plate in 0.3% agar with Iscove's modification of Dulbecco's medium, 25% fetal calf serum and 5% vol/vol human placental-conditioned medium. Colonies with 40 cells or more after 14 days of incubation at 37°C with 5% carbon dioxide were counted as CFU-GM. The reference mean value is 110 × 10 3 /l with a 95% range of 23-490 × 10 3 /l in our laboratory.
Threshold values for PBSCT
Cell yield was considered to be sufficient for PBSC transplantation if more than 2 × 10 6 CD34 + cells/kg body weight (bw) or more than 15 × 10 4 CFU-GM/kg bw was harvested.
Statistical analysis
The cell yields of the initial collection after chemotherapy plus G-CSF and the subsequent collection with increased dose of G-CSF were tested for significance by nonparametric one-tailed Wilcoxon paired-sample test. The number of patients with cell yields above and below the threshold values for PBSCT were tested with one-tailed Fisher's exact test.
Results
Patients
Two of the 10 patients were female and the median age was 53 years with a range of 3 to 66 years. There were seven patients with relapsed non-Hodgkin's lymphoma, one with multiple myeloma, one with progressive chronic lymphocytic leukemia and one with progressive optic glioma. Bone marrow involvement by disease was present in six patients at initial diagnosis and in five at mobilization. Figure 1 shows the serial changes and Figure 2 the mean levels of CD34 + cells in the peripheral blood during the two phases of mobilization. The mean levels were calculated as the average of CD34 + cell levels on the days of apheresis during each phase of mobilization. Seven out of the 10 patients had an increase of circulating CD34
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+ cells in the blood after G-CSF dose escalation.
Apheresis for PBSC collection was not attempted in two patients after initial mobilization with chemotherapy plus G-CSF because of persistently low circulating CD34 + cell counts. For the same reason, three patients did not have collection after an increased dose of G-CSF. One patient was not collected in both phases of the mobilization program.
Cell yields
The total yield and yield per apheresis in terms of MNC, CD34
+ cells and CFU-GM with the two phases of mobilization are summarized in Table 1 .
The total MNC yield increased significantly from a /kg bw (range 0.00-0.14) to 0.67 × 10 6 /kg bw (range 0.00-3.05) (P Ͻ 0.01). The total yield of CD34 + cells in the harvests /kg bw (range 0.00-57.70) (P Ͻ 0.01). Among the six patients who had aphereses during both phases of the mobilization program, the median increase in total MNC, CD34
+ cells and CFU-GM collected were eight-fold, 45-fold and 33-fold, respectively.
Threshold yield for PBSCT
After the second phase of higher dose G-CSF, six of the patients (60%) who did not have sufficient PBSC in the first phase of mobilization had more than 2 × 10 6 CD34 + cells/kg bw. Four patients (40%) had more than 15 × 10 4 CFU-GM/kg bw. There were significantly more patients reaching the thresholds (P Ͻ 0.01 and Ͻ0.05, respectively) after higher dose G-CSF.
Patient outcome
The six patients who were successfully salvaged with the augmented dose of G-CSF underwent high-dose therapy and PBSCT. Five had successful engraftment while one died early post-transplantation prior to engraftment. On the other hand, of the four patients failing the dose-escalation strategy, two required additional marrow harvesting to obtain adequate progenitor cells for transplantation. No attempt of re-mobilization was made in the other two.
Discussion
In this report, 10 patients who failed to attain a sufficient PBSC yield after initial mobilization with chemotherapy plus G-CSF were then administered a higher dose of G-CSF. Sixty percent of patients reached the CD34 + threshold. Our results demonstrated a dose-dependent effect of G-CSF to increase cell yield in PBSC mobilization with a combination of chemotherapy and HGF. The total yield, as well as yield per apheresis in terms of MNC, CD34
+ cells and CFU-GM, was significantly increased. Moreover, the fold increases in CD34
+ cells and CFU-GM were much higher than the fold increases in MNC. This suggests a preferential release of hematopoietic progenitor cells into the circulation from the marrow at a higher dose of G-CSF.
A dose-dependent response has been reported when G-CSF is used alone for mobilization up to a dose of 10 to 16 g/kg/day. 12, 13 In the literature, the dose of G-CSF used in combination with chemotherapy for mobilizing PBSC is usually between 3 and 6 g/kg/day. 4, 14, 15 At our center, the standard dose is G-CSF 5 g/kg/day. However, by increasing the dose of G-CSF from 5 g/kg/day to 10 g/kg/day in nine out of 10 patients, it was possible to salvage the mobilization program in a significant proportion of patients who failed with the standard dose. It would be interesting to see if the salvage rate can be further improved with even higher doses of G-CSF. Indeed, with the one child in the study, a dose escalation from 10 g/kg/day to 15 g/kg/day was required to secure a sufficient harvest. There was an earlier attempt to mobilize PBSC in this child a month before using the same chemotherapy plus G-CSF 5 g/kg/day, which also failed to achieve sufficient yield.
The mechanism(s) by which G-CSF mobilizes PBSC is being studied in many laboratories including ours. It is probably not linked to the neutrophilic leukocytosis because of the several days' time lag between the rise of neutrophil count and the rise of blood progenitor cell levels. Similarly, the G-CSF-induced changes in ␣ 4 ␤ 1 and ␣ 5 ␤ 1 integrins occur in minutes and are not consistent with the clinical time course of mobilization. 16 We have shown that increased bone turnover occurs after 4 days of G-CSF administration as measured by reduction in serum osteo calcin (osteoblast activity) and an increase in urinary deoxypyridinoline (osteoclast activity). However, they return to normal on cessation of G-CSF. Furthermore, G-CSF administration to mice increases osteoclast number and activity. Even more interestingly, osteoclastic activity leads to high local concentration of calcium ions, 17 which inactivates ␣ 4 ␤ 1 integrin-mediated adhesion of CD34 + cells to fibronectin, a major component of the bone marrow stroma. Hence it is possible that increasing G-CSF doses may lead to more effective mobilization through its indirect modulation of the adhesive interaction between hematopoietic progenitor cells and the marrow micro-environment. 18 Besides the mobilization regimen, patient factors such as bone marrow involvement by disease 19 and the extent of prior chemotherapy 2, 20 have been reported to influence the cell yield. The number of patients in this study is too small for us to assess properly whether these factors are associated with the failure or success of the salvage strategy. Nevertheless, it was noted that all four patients who failed to achieve the threshold values even after higher dose G-CSF had bone marrow involvement at some stage of their disease, compared to only two of the other six patients with successful mobilization.
More important clinically is the ability to predict the patients who are not likely to give sufficient yield with the standard lower dose of G-CSF. Fruehauf et al 21 reported measuring steady-state peripheral blood progenitors as a means to estimate the yield after combined chemotherapy and G-CSF mobilization. It may be possible to monitor the level of peripheral blood progenitors before and during mobilization as a guide to dose modification of HGF. This would enable early dosage adjustment to suit individual patients and to improve the success rate and cost effectiveness of the mobilization program.
Better understanding of the mechanism of mobilization may provide insight to the development of mobilization protocols for patients who are difficult to mobilize. Nevertheless, our method of G-CSF dose escalation as late as the third week for initial failure of PBSC mobilization with chemotherapy and G-CSF may represent a simple strategy for such patients.
